Background: New cases of cancer and cancer-related deaths are high in Mongolia. Therefore, it is a priority to develop anticancer drugs based on recent scientific achievements, successes, and major theoretical concepts. Pharmaceutical nanotechnology, including pharmaceutical engineering, is developing rapidly, and the problem of drug delivery to tumor-triggered organs, tissues, and cells has been studied at many levels. Drug delivery systems are divided into organic, inorganic, and complex nanocarriers based on their physicochemical properties. The specificity of drug targeting to tumor-triggered organs, tissues, and cells can be explained by passive and active targeting mechanisms. The passive delivery mechanism of drugs to tissues and cells is related to the tumor microenvironment and vascularization, while the active delivery mechanism is related to the principle of binding to specific receptors on the surface of tumor-transformed cells and releasing the drugs into the cell. Conclusion Extensive research in this area in Mongolia has many benefits for the development of anti-cancer drugs.

Abstract We have worked on the research related with total flavonoid isolated Rhododendron Adamsii Rehder, which enhance and restore physical energy and reduce mental pain. According to the result, the highest amount (2.4±0.007%) of the total flavonoids was found in the 40% ethanol extract of Rhododendron Adamsii Rehder at 60 minutes of extraction time. Subsequently, the granulated formulation from the extract of Rhododendron Adamsii Rehder was prepared by using 4% of gelatin, 4% of polyvinylchloride and 4% of carboxymethyl cellulose. The fluidity and pouring weight of the granule was evaluated and 4% of gelatin was chosen as the suitable binder for the formulation. In conclusion, we have successfully developed the granulated formulation from Rhododendron Adamsii Rehder.

Introduction: Nowadays, there is a growing trend to use natural medicines with low side effects, and research on medicinal raw materials used in traditional medicine has become more widespread. Therefore, it is important to obtain a suitable drug form from Plantago Major L and to conduct chemical and pharmaceutical technology research. Material and method: The research was conducted in the pharmaceutical industry and technology laboratory. A granule formulation with several variants consisting of a concentrated extract and excipients was obtained. The sum of flavonoids of Plantago Major L extracts and Granular Dosage Forms was detected by thin-layer chromatography in a suitable solvent system prepared in the ratio of ethyl acetate, formic acid, glacial acetic acid, and water (100: 11:11:26). The total flavonoid content of the drug forms was determined by spectrophotometry. Result: Technological researches were carried out with lactose and glucose fillers, gelatin 8%, polyvinyl chloride (PVP) 6%, starch 5% binders, talc 1%, magnesium stearate 1% sliding and lubricating agents and the wet granulation method was used to obtain granules in several variants and was determined by using parameters such as particle spill weight and flow quality. In this research, the flow rate of Plantago Major L grains with lactose as a filler and PVP as a binder was -2.8 ± 0.18 g / sec (p <0.001) and the spill weight was -0.54 ± 0.03 g /cm3 (p <0.001). Based on the results of the above research, lactose was added as a filler, PVP as a binder, 6% as a slide and lubricant, 3% as talc and 1% as magnesium stearate, and the granular drug technology was developed by wet granulation. Analysis of the total flavonoids by thin-layer chromatography revealed the same level of yellow-brown spots (Rf = 0.4) on the plate. The total flavonoid content of the granules from Plantago Major L was 3.8 ± 0.2% (p <0.002). Conclusion In this study, a simple and suitable drug formulation from Plantago Major L was successfully obtained and it was a basic research to make new drug formulations in further needs.

Background: Spinal Muscular Atrophy (SMA), an autosomal recessive disorder characterized by lower motor neuron loss, leads to progressive muscle weakness and atrophy. With a neonatal incidence ranging from 1:6000 to 1:11000, individuals affected by SMA face challenges in locomotor function. The advent of newborn screening tests, early diagnostic techniques, and the introduction of gene therapy have, however, shown promise in enabling the acquisition of these motor skills. Objective: This review article seeks to shed a light on current understandings of the epidemiology, clinical presentations, diagnostic methods, and treatments for spinal muscular atrophy, highlighting cutting edge approaches within the discipline. Methods: A thorough search was conducted on PubMed, Cochrane, National Institutes of Health, and Web of Science databases for recent research articles concerning SMA’s incidence, prevalence, clinical manifestations, early detection, genetic testing and contemporary gene therapy. Results: The prevalence of SMA stands at 1-2 cases per 100,000 population, with an incidence of approximately 8 cases per 100,000 live births. Pre-1995 studies exhibited varying prevalence rates due to using non molecular-biological methods, small localized populations, diagnostic errors, and regional characteristics. Diagnosis involving Multiplex ligation-dependent probe amplification (MLPA), quantitative polymerase chain reaction (qPCR), or next-generation sequencing (NGS) analysis to confirm SMN1 and SMN2 gene status aids in identifying carriers and SMA subtypes. Countries implementing newborn screening programs have demonstrated early SMA detection in asymptomatic newborns, contributing to reduced mortality and disability rates. Currently, several types of gene therapy are being used in the treatment of SMA. Conclusion The epidemiology of SMA varies between countries and regions. It is fully possible to confirm the disease, identify carriers and subtypes. The inclusion of SMA in newborn early detection programs is crucial for reducing infant mortality and disability, and several gene therapies have received approval from relevant authorities for SMA treatment. In Mongolia, it is possible to introduce tests to confirm the disease and determine carriers and subtypes.